This review article summarizes the efficacy, safety, and clinical attributes of liraglutide among overweight or obese patients with or without comorbidities. Areas Covered: A MEDLINE search, from 1970 to June 2016, was conducted using key terms 鈥 glucagon-like peptide-1 receptor agonist, ...
利拉鲁肽是一款新型胰高血糖素样肽-1受体激动剂（ GLP⁃１ＲＡ），目前主要通过基因重组改造的酒酿...
Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney event...
胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)是一类治疗2型糖尿病的重要新药,因其卓越的有效性,引发了国际社会的广泛关注。人体中GLP-1主要由肠道L细胞分泌,在促进胰岛素分泌同时又能减少胰高血糖素...
[12]Noyan-Ashraf, M.H., Momen, M.A., Ban, K., Sadi, A.M., Zhou, Y.Q., Riazi, A.M., et al. 2009. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975-983. ...
7 Liu, Q. et al. Cyclobutane derivatives as novel nonpeptidic small molecule agonists of glucagon-like peptide-1 receptor.J Med Chem55, 250-267, doi:10.1021/jm201150j (2012). 8 Fan, H. et al. The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating...
attributed to two GLP-1 agonists authorised for weight loss and type 2 diabetes: liraglutide and sernaglutide in injectable or oral forms (1,2).As of late 2023, the European summaries of product characteristics (SmPCs) for products containing a GLP-1 agonist make no mention of this type of...
H. et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58, 975–983 (2009). Article CAS PubMed PubMed Central Google Scholar Nikolaidis, L. A. et al. Effects of glucagon-like peptide-1 in ...
Despite years of research in the field of type 1 diabetes, patients with the disease remain without a therapeutic agent that can alter the underlying immune response in a clinically beneficial way. Glucagon-like peptide 1 agonist therapies have shown some promising effects in terms of positively af...
度拉糖肽在血糖控制相对好的2型糖尿病人群中仍可以显著改善CVD发生风险的科学意义是REWIND研究进一步提供了GLP-1 RA具有独立于血糖水平的心血管保护作用的临床证据,这为在非糖尿病人群中(如糖尿病前期、1型糖尿病或代谢综合征人群)探讨GLP-1 RA的心血管保护作用提供了建立科学假设的基础。